Market News & Trends
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
DURHAM, N.C., Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
SAN DIEGO, - Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant…
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy, ART-123 (Recomodulin, to enhance treatment options worldwide
Chelmsford, MA; Novi, MI; Düsseldorf, Germany; and Tokyo, Japan - Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123…
Aenova expands cold chain capabilities with new state-of-the-art warehouse at its sterile site in Latina
Latina (Italy), Aenova, a leading global contract development and manufacturing organization (CDMO), is investing in a new cold chain warehouse at its sterile site in…
PharmNovo announces CTA submission for lead candidate PN6047, a next generation selective Delta Opioid Receptor Agonist (DORA) for treatment of neuropathic pain
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the basis…
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
Genitourinary Tumor Study Ongoing with Active Screening and Enrollment MILAN and NEW YORK, Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a…
atai Life Sciences Announces $50 Million Private Placement Financing
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1…
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan)
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN Non-dilutive financing further…
Aptamer Group Identifies Novel Target to Enable Cell-Specific Gene Therapy for Liver Fibrosis
Aptamer unveils novel biomarker for targeted liver fibrosis therapy Optimer breakthrough targets liver scarring cells, positioning Aptamer in $20bn fibrosis market Aptamer Group plc today…
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif.,…
Simtra BioPharma Solutions Expands Halle/Westfalen, Germany Facility with the Addition of a New Production Building
HALLE (WESTFALEN), Germany, Simtra BioPharma Solutions announced today that it completed the construction of its new production manufacturing building at its campus in Halle, Germany. As…
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony
Pharmaceutical service provider expands its footprint in the greater Chicago area Production site expected to be fully operational by the end of 2029 Modern site…
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
TARPON SPRINGS, Fla., Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor…
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
RESEARCH TRIANGLE PARK, N.C., Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and…
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab)
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients…
Sever Pharma Solutions Announces Commercialization of New Aseptic Fill and Finish Line for Prefilled Syringes in Malmö, Sweden
MALMÖ, SWEDEN– Sever Pharma Solutions, a leading CDMO, proudly announces the commercialization of its new state-of-the-art aseptic fill and finish line for prefilled syringes, capable…
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
HOUSTON, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced…
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Saint-Louis, France and Dublin, Ireland, Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat…
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
BOSTON, Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for…
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks…
